Cellectis S.A-Product Pipeline Review-2015

Cellectis S.A-Product Pipeline Review-2015

  • Products Id :- GMDHC07693CDB
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cellectis S.A-Product Pipeline Review-2015


Global Markets Direct's, 'Cellectis S.A-Product Pipeline Review-2015', provides an overview of the Cellectis S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellectis S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Cellectis S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Cellectis S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Cellectis S.A.'s pipeline products

Reasons To Buy

Evaluate Cellectis S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Cellectis S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Cellectis S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Cellectis S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellectis S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Cellectis S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Cellectis S.A. Snapshot 6

Cellectis S.A. Overview 6

Key Information 6

Key Facts 6

Cellectis S.A-Research and Development Overview 7

Key Therapeutic Areas 7

Cellectis S.A-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Cellectis S.A-Pipeline Products Glance 14

Cellectis S.A-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Cellectis S.A-Drug Profiles 16

UCART-123 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

UCART-19 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

UCART-22 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Gene Therapy for Hemophilia 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

S-2 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

S-3 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

S-4 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

S-5 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

S-6 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

S-7 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Stem Cell Therapy for Diabetes 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

UCART-33 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

UCART-38 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

UCART-5T4 29

Product Description 29

Mechanism of Action 29

R&D Progress 29


Product Description 30

Mechanism of Action 30

R&D Progress 30


Product Description 31

Mechanism of Action 31

R&D Progress 31


Product Description 32

Mechanism of Action 32

R&D Progress 32

Cellectis S.A-Pipeline Analysis 33

Cellectis S.A-Pipeline Products by Target 33

Cellectis S.A-Pipeline Products by Route of Administration 34

Cellectis S.A-Pipeline Products by Molecule Type 35

Cellectis S.A-Pipeline Products by Mechanism of Action 36

Cellectis S.A-Recent Pipeline Updates 37

Cellectis S.A-Dormant Projects 41

Cellectis S.A-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

Cellectis S.A., Key Information 6

Cellectis S.A., Key Facts 6

Cellectis S.A-Pipeline by Indication, 2015 8

Cellectis S.A-Pipeline by Stage of Development, 2015 10

Cellectis S.A-Monotherapy Products in Pipeline, 2015 11

Cellectis S.A-Partnered Products in Pipeline, 2015 12

Cellectis S.A-Partnered Products/ Combination Treatment Modalities, 2015 13

Cellectis S.A-Preclinical, 2015 14

Cellectis S.A-Discovery, 2015 15

Cellectis S.A-Pipeline by Target, 2015 33

Cellectis S.A-Pipeline by Route of Administration, 2015 34

Cellectis S.A-Pipeline by Molecule Type, 2015 35

Cellectis S.A-Pipeline Products by Mechanism of Action, 2015 36

Cellectis S.A-Recent Pipeline Updates, 2015 37

Cellectis S.A-Dormant Developmental Projects,2015 41

Cellectis S.A., Subsidiaries 42

List of Figures

Cellectis S.A-Pipeline by Top 10 Indication, 2015 8

Cellectis S.A-Pipeline by Stage of Development, 2015 10

Cellectis S.A-Monotherapy Products in Pipeline, 2015 11

Cellectis S.A-Pipeline by Target, 2015 33

Cellectis S.A-Pipeline by Molecule Type, 2015 35

Cellectis S.A-Pipeline Products by Top 10 Mechanism of Action, 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Cellectis S.A.; Cellectis S.A-Key Therapeutics; Cellectis S.A-Pipeline Overview and Promising Molecules; Cellectis S.A-News; Cellectis S.A-Latest Updates; Cellectis S.A-Pipeline; Cellectis S.A-Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com